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Abstract
Introduction
Craniopharyngiomas (CPs) are benign neoplasms and most common suprasellar tumors. They are more
frequent in children, contributing to a significant number of intracranial tumors in the pediatric population
and are thought to be arising either from the epithelial remnant cells of the craniopharyngeal duct or from
the adenohypophysis epithelium. Two subtypes of CPs exist, namely, adamantinomatous
craniopharyngioma (ACP) and papillary craniopharyngioma (PCP). ACP is more common in children with a
relatively aggressive clinical course and more frequent relapses than PCP. The study objective was to
evaluate the clinicopathological features of CP in our population.
Methods
We conducted a retrospective observational study in the Department of Histopathology at Aga Khan
Hospital, Karachi, Pakistan, over a period of 15 years, from January 2001 to December 2015. All CP cases
were included in the study. A total of 207 cases were diagnosed during this period by histopathologists based
on histologic features. All slides were retrieved, and diagnosis was confirmed after a reexamination of slides.
Results
We found that the mean age of diagnosis was 25.59±14.71 years, and the median follow-up time was 7 (3-19)
years. The number of male patients was 136 (65.7%) and the number of female patients was 71 (34.3%). The
most common tumor site was suprasellar (71.5%) followed by the sellar and temporal lobe (12.1% and 6.8%,
respectively). The most common complaints were headache (21.7%), followed by loss of vision/decreased
vision (16.4%) and vomiting (5.3%). The overall survival rate was 95.2% with a recurrence rate of 5.8%. A
significant association of survival was noted with tumor recurrence.
Conclusion
CP is a rare brain tumor with good overall survival. We found a low recurrence rate of CP in our study.
However, recurrence was found to be the most important factor determining survival in patients with CP.
Categories: Pathology, General Surgery, Neurosurgery
Keywords: craniopharyngioma, papillary craniopharyngioma, adamantinomatous craniopharyngioma
Introduction
Craniopharyngioma (CP) is a tumor of sellar and suprasellar areas with two histologic subtypes. The
adamantinomatous craniopharyngioma (ACP) subtype is usually seen in childhood and is more common,
whereas the papillary craniopharyngioma (PCP) subtype is almost exclusive to the adult population [1]. The
two subtypes differ in their clinical behavior and overall features. The papillary type is usually indolent,
whereas the adamantinomatous type has a relatively aggressive clinical course [2]. The most reported
symptoms are headache, decreased/loss of vision, and neuroendocrine abnormalities (hormonal changes,
personality changes, etc.). The incidence from recent studies appears to be high in males compared to
females [3]. However, previous studies had shown an equal incidence in males and females. Malignant
transformation is infrequent and usually occurs after multiple recurrences of CP [4]. ACP is relatively
common and tends to recur more frequently than PCP whereas PCP has a benign clinical course with less
frequent relapses. The usual treatment approach for both subtypes is resection followed by radiotherapy.
The study objective was to evaluate the clinicopathological features of CP in our population.
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Materials And Methods
We conducted a retrospective observational study in the Department of Histopathology at Aga Khan Hospital
(Karachi, Pakistan) over a period of 15 years, from January 2001 to December 2015. All CP cases were
included in the study. A total of 207 cases were diagnosed during this period by histopathologists based on
histological features. All slides were retrieved, and diagnosis was confirmed after a reexamination of
slides. All specimens were received in the histopathology lab. After gross examination and specimen
measurement, the tissues were submitted entirely for histopathological examination. A diagnosis of CP was
rendered based on histopathological findings. PCP was characterized by papillary (with fibro-vascular cores)
and cauliflower-like morphology, composed of non-keratinizing squamous epithelium. Alternatively, ACP
was defined by trabeculae and sheets, with nuclear palisading and stellate reticulum. Nodules of anucleated
squames (wet keratin) are characteristic of ACP (Figure 1).
FIGURE 1: Craniopharangioma, adamantinomatous subtype: (A) H&E-
stained section at 40x magnification showing sheets and trabeculae of
squamous epithelium; (B) H&E-stained section at 100x magnification
revealing wet keratin (arrow); (C) H&E-stained section at 400x
magnification depicting stellate reticulum (arrow)
H&E, hematoxylin and eosin
Data analysis was performed using Statistical Package for the Social Sciences, Version 26.0 (IBM Corp,
Armonk, USA). Independent t-test and Fisher’s exact tests were used to check the association. Survival
analysis was done by the Kaplan-Meier method. P-values < 0.05 were considered as significant.
Results
We reviewed a total of 207 cases and determined their clinicopathological features. The variables that were
studied included age, site, symptoms, gender, tumor subtype, recurrence, and survival. We found that the
mean age of diagnosis was 25.59±14.71 years, and the median follow-up time was 7 (3-19) years. There were
136 (65.7%) male patients and 71 (34.3%) female patients. The most common site was the suprasellar
(71.5%), followed by the sellar and temporal lobe (12.1% and 6.8%, respectively). The most common
complaints were headache (21.7%) followed by loss of vision/decreased vision (16.4%) and vomiting (5.3%).
The overall survival rate was 95.2% with a recurrence rate of 5.8% (Table 1).
Clinicopathologic characteristics Values
Age (years), mean±SD 25.59±14.71
Follow-up (years), median (range) 7 (3–19)
Gender  
Male, n (%) 136 (65.7)
Female, n (%) 71 (34.3)
Site  
Supraseller, n (%) 148 (71.5)
Sellar, n (%) 25 (12.1)
Frontal, n (%) 11 (5.3)
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Sellar and suprasellar, n (%) 9 (4.3)
Temporal, n (%) 14 (6.8)
Headache  
Yes, n (%) 45 (21.7)
No, n (%) 162 (78.3)
Vomiting  
Yes, n (%) 11 (5.3)
No, n (%) 196 (94.7)
Decreased/loss of vision  
Yes, n (%) 34 (16.4)
No, n (%) 173 (83.6)
Fever  
Yes, n (%) 5 (2.4)
No, n (%) 202 (97.6)
Generalized weakness  
Yes, n (%) 5 (2.4)
No, n (%) 202 (97.6)
Tumor type  
Papillary, n (%) 2 (1)
Adamantinomatous, n (%) 205 (99)
Recurrence  
Yes, n (%) 12 (5.8)
No, n (%) 195 (94.2)
Survival status  
Alive, n (%) 197 (95.2)
Expired, n (%) 10 (4.8)
TABLE 1: Clinicopathological features of the population under study
SD, standard deviation
No significant association of clinicopathological features with recurrence was noted (Table 2).
Clinicopathologic characteristics
Values
P-valueRecurrence
Yes (n=12) No (n=195)
Age (years)*, mean±SD 28.00±19.43 25.44±14.42 0.205
Gender**    
Male, n (%) 8 (66.7) 128 (65.6)
1.000
Female, n (%) 4 (33.3) 67 (34.4)
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Site**    
Supraseller, n (%) 9 (75) 139 (71.3)
0.606
Sellar, n (%) 1 (8.3) 24 (12.3)
Frontal, n (%) 0 (0) 11 (5.6)
Sellar and suprasellar, n (%) 0 (0) 9 (4.6)
Temporal, n (%) 2 (16.7) 12 (6.2)
Headache**    
Yes, n (%) 3 (25) 42 (21.5)
0.726
No, n (%) 9 (75) 153 (78.5)
Vomiting**    
Yes, n (%) 0 (0) 11 (5.6)
1.000
No, n (%) 12 (100) 184 (94.4)
Decreased/loss of vision**    
Yes, n (%) 2 (16.7) 32 (16.4)
1.000
No, n (%) 10 (83.3) 163 (83.6)
Fever**    
Yes, n (%) 0 (0) 5 (2.6)
1.000
No, n (%) 12 (100) 190 (97.4)
Generalized weakness**    
Yes, n (%) 1 (8.3) 4 (2.1)
0.260
No, n (%) 11 (91.7) 191 (97.9)
Tumor type**    
Papillary, n (%) 0 (0) 2 (1)
1.000
Adamantinomatous, n (%) 12 (100) 193 (99)
Survival status**    
Alive, n (%) 10 (83.3) 187 (95.9)
0.107
Expired, n (%) 2 (16.7) 8 (4.1)
TABLE 2: Association of clinicopathologic characteristics of craniopharangioma with tumor
recurrence
SD, standard deviation
*Independent t-test was applied.
**Fisher’s exact test was applied.
Similarly, no significant association of survival status was noted with clinicopathological features (Table 3).
Clinicopathologic characteristics
Values
P-valueSurvival status
Alive (n=197) Expired (n=10)
Age (years)*, mean±SD 25.79±14.65 21.60±16.13 0.380
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Gender**    
Male, n (%) 128 (65) 8 (80)
0.499
Female, n (%) 69 (35) 2 (20)
Site**    
Supraseller, n (%) 138 (70.1) 10 (100)
0.673
Sellar, n (%) 25 (12.7) 0 (0)
Frontal, n (%) 11 (5.6) 0 (0)
Sellar and suprasellar, n (%) 9 (4.6) 0 (0)
Temporal, n (%) 14 (7.1) 0 (0)
Headache**    
Yes, n (%) 43 (21.8) 2 (20)
1.000
No, n (%) 154 (78.2) 8 (80)
Vomiting**    
Yes, n (%) 10 (5.1) 1 (10)
0.428
No, n (%) 187 (94.9) 9 (90)
Decreased/loss of vision**    
Yes, n (%) 32 (16.2) 2 (20)
0.670
No, n (%) 165 (83.8) 8 (80)
Fever**    
Yes, n (%) 5 (2.5) 0 (0)
1.000
No, n (%) 192 (97.5) 10 (100)
General weakness**    
Yes, n (%) 5 (2.5) 0 (0)
1.000
No, n (%) 192 (97.5) 10 (100)
Tumor type**    
Papillary, n (%) 2 (1) 0 (0)
1.000
Adamantinomatous, n (%) 195 (99) 10 (100)
Recurrence**    
Yes, n (%) 9 (4.6) 1 (10)
0.397
No, n (%) 188 (95.4) 9 (90)
TABLE 3: Association of clinicopathologic characteristics of craniopharyngioma with survival
status
SD, standard deviation
*Independent t-test was applied.
**Fisher’s exact test was applied.
Alternatively, significant association of survival was noted with tumor recurrence (Figure 2).
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FIGURE 2: Association of recurrence with survival status in patients
with craniopharyngioma
Discussion
CP is the most frequent neoplasm of suprasellar and sellar region with ACP being approximately nine times
more prevalent than PCP [1,2]. Some studies from Pakistan have found the incidence to be greater in the
male population [3], but overall CP affects both males and females equally [1-3]. Malignant transformation
occurs in CP, especially after multiple recurrences, and some of the reported cases were treated with
radiotherapy [4]. Malignant transformation was reported in patients with giant sellar masses and it is
recommended to take extra caution if the size of the lesion is large [4].
The size of PCP is usually smaller and the recurrence rate is lower than ACP [5]. Sanford reported the results
of a survey and suggested a very good overall outcome in children who were treated with limited surgery and
irradiation compared to the attempted total resection [6]. Wara et al. also reported a 77% 10-year disease-
free survival after treatment with radiation and surgery, and advised to follow the patients who underwent
total resection without radiation [7].
Schoenfeld et al. also reported better overall outcomes with surgery and radiation compared to gross total
resection (GTR) [8]. Other studies also reported that the incidences of endocrinopathies were significantly
more with GTR compared with subtotal resection (STR) and radiation [9]. Recent studies have shown that
the history of radiation therapy (instead of surgery) is more effective in reducing the resection extent in
recurrent cases of craniopharyngioma [10,11].
Based on location and size, differential diagnosis of CP includes pituitary adenoma, epidermoid cyst, and
Rathke cleft cyst with squamous metaplasia. Pituitary adenoma is characterized by sheets of monotonous
round cells with neuroendocrine appearance. An epidermoid cyst is unilocular lined by keratinizing
squamous epithelium. Finally, a Rathke cleft cyst also contains ciliated or mucinous lining that helps in
differentiation. In addition, ACPs sometimes show reactive gliosis (piloid gliosis), which sometimes causes
confusion and may lead to an erroneous diagnosis of pilocytic astrocytoma. However, the presence of wet
keratin and squamous epithelium helps in the correct diagnosis. There is limited role of
immunohistochemistry (IHC) in the diagnosis of CP, although ACP is positive with CK7, CK8, CK19 and beta-
catenin. PCP is positive with BRAF V600E IHC, while ACP is negative. As far as molecular genetics is
concerned, ACP is characterized by mutations that activate Wnt pathway gene CTNNB1 encoding β-catenin
in most of the cases, while PCP is characterized by BRAF V600E mutation in more than 90% of cases [1,2,6].
CPs tend to recur and can cause significant mortality and morbidity due to their critical location and
hormonal imbalances, and therefore the recommendation is to prefer STR and radiation therapy over GTR
[12].
The limitations of our study included a retrospective study design and limited sample size, especially cases
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of PCP, and therefore, the association of tumor type with recurrence and survival could not be determined.
In addition, lack of availability of radiological findings is yet another limitation of the study. Moreover, data
regarding GTR versus STR were not available to evaluate the outcome in different treatment groups.
Conclusions
CP is a rare suprasellar brain tumor with distinguished histological features. In our study, the ACP subtype of
CP was far more frequent than the PCP subtype. We found an overall low recurrence rate and good survival
in patients of CP in our study. We also noted a significant association of disease recurrence of CP with
survival in our study. However, more studies are required to have a better idea of clinical course and
prognosis of CP in Pakistan, especially the outcome in different treatment groups, for instance, GTR
versus STR with radiation.
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